Top Page
Aurora Spine
(ASG)
Aurora Spine (ASG) vs. iShares MSCI Canada ETF (EWC)
Aurora Spine Business Overview & Revenue Model
Aurora Spine Earnings Call Summary
Aurora Spine Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 16.90M | 14.52M | 14.88M | 10.54M | 8.65M | 11.15M | Gross Profit |
| 10.21M | 8.21M | 7.81M | 4.83M | 3.47M | 3.55M | EBIT |
| -457.60K | -446.20K | -1.57M | -2.71M | -1.25M | -1.25M | EBITDA |
| 580.32K | -446.20K | -469.27K | -1.90M | -573.86K | -692.83K | Net Income Common Stockholders |
| -635.51K | -1.68M | -1.50M | -2.36M | -232.09K | -1.25M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 856.50K | 766.83K | 423.40K | 3.17M | 1.71M | 444.74K | Total Assets |
| 6.84M | 11.99M | 10.12M | 10.56M | 7.16M | 6.67M | Total Debt |
| 2.02M | 3.65M | 2.97M | 2.38M | 2.34M | 2.41M | Net Debt |
| 1.16M | 2.88M | 2.55M | -793.02K | 632.23K | 1.97M | Total Liabilities |
| 3.88M | 6.69M | 5.81M | 4.99M | 3.87M | 4.91M | Stockholders Equity |
| 2.96M | 5.30M | 4.32M | 5.57M | 3.28M | 1.77M |
| Cash Flow | Free Cash Flow | ||||
| -524.64K | -1.41M | -2.43M | -2.85M | -245.07K | -285.99K | Operating Cash Flow |
| -136.05K | -935.06K | -1.56M | -2.13M | 309.57K | 729.00 | Investing Cash Flow |
| -388.58K | -479.13K | -873.21K | -720.61K | -554.64K | -283.87K | Financing Cash Flow |
| 1.03M | 1.76M | -318.15K | 4.31M | 1.51M | -128.62K |
Aurora Spine Technical Analysis
Aurora Spine Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | C$118.17M | ― | -8.34% | ― | 0.69% | -95.27% | |
58 Neutral | C$25.76M | ― | -23.87% | ― | 18.97% | 17.57% | |
54 Neutral | C$229.31M | ― | -66.14% | ― | 51.21% | 15.33% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
50 Neutral | C$21.98M | ― | -163.62% | ― | 113.85% | 11.38% | |
46 Neutral | C$47.08M | ― | -291.48% | ― | -8.63% | 7.04% | |
44 Neutral | C$17.16M | ― | 207.08% | ― | 280.56% | -7.28% |
Aurora Spine Corporate Events
Aurora Spine Corporation announced its participation in the Lytham Partners Spring 2025 Investor Conference, where it will present a webcast and host one-on-one meetings with investors. This participation underscores Aurora Spine’s commitment to engaging with investors and stakeholders, potentially enhancing its market presence and investor relations.
Aurora Spine Corporation announced record financial results for the first quarter of 2025, with a 10% increase in revenue compared to the previous year. The company received FDA clearance for its AERO Facet Fusion System and reported significant sales growth in its DEXA-C cervical implant. Aurora Spine is optimistic about future growth, driven by its robust R&D efforts and upcoming product launches, including the DEXA-L series and the AERO system, which are expected to enhance patient outcomes and expand market reach.
Aurora Spine Corporation announced the release schedule for its first quarter fiscal 2025 financial results, which will be filed on May 21, 2025, with a press release and investor conference call to follow on May 22, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
Aurora Spine Corporation reported a record revenue of $17.6 million for fiscal year 2024, marking a 21% increase from the previous year. The company’s financial success was driven by a 135% surge in sales of the SiLO-TFX SI joint implant, expansion of its internal sales force, and increased margins. The company also achieved its first annual positive EBITDAC and is poised for further growth with the recent FDA clearance of its new AERO product platform.
Aurora Spine Corporation announced the release of its fourth quarter and fiscal year 2024 financial results, scheduled for April 28, 2025. The company also clarified an error in its management information circulars regarding its stock option plan, ensuring the correct version will be included in future shareholder meeting materials.
Aurora Spine has announced the resignation of James Snow from its Board of Directors as he transitions to the role of Regulatory Affairs and Quality Assurance Manager within the company. This move highlights Snow’s commitment to Aurora Spine’s future and his belief in the company’s innovative technologies, as he aims to enhance compliance and quality across their product portfolio.
Aurora Spine announced the publication of a biomechanical study in the journal Neurospine, demonstrating the superior performance of its SiLO TFX ™ Sacroiliac Fusion System compared to traditional methods. The study highlights the system’s ability to reduce joint motion and preserve bone integrity, offering a promising alternative for sacroiliac joint fusion. The findings support Aurora Spine’s commitment to optimizing patient outcomes and reinforce its position as a leader in spinal implant technology.
Aurora Spine has received FDA 510(k) clearance for its AERO Facet Fusion System, a minimally invasive device designed for patients with facet joint-related pain or instability. The system, which can be used independently or alongside larger spinal fusion surgeries, is expected to begin initial surgeries in late Q3 2025. The AERO system is engineered to promote bone fusion while minimizing soft tissue disruption, aligning with Aurora Spine’s commitment to patient-first innovations. The clearance is seen as a significant milestone for the company, with expectations that the AERO system will drive growth and improve patient care in spinal surgery.
Aurora Spine Corporation announced its participation in the 2025 American Academy of Orthopaedic Surgeons Annual Meeting, where it will showcase its advanced spinal surgery products such as the DEXA-C cervical cage and the SiLO TFX SI Fusion System. This event provides Aurora Spine an opportunity to connect with leading orthopaedic surgeons and highlight its unique technologies designed to improve surgical outcomes and cater to specific patient needs, potentially strengthening its position in the spinal implant industry.
Aurora Spine Corporation has completed patient enrollment for its REFINE study, which is the first prospective, multi-center, multi-specialty trial to evaluate the safety and efficacy of lumbar interlaminar fusion devices. This study aims to provide robust, long-term insights into patient outcomes and is expected to influence future clinical decision-making and elevate the standard of care in spinal fusion. The results will be presented at the ASPN annual conference in July 2025, highlighting Aurora Spine’s commitment to evidence-based innovation and offering a less invasive alternative to traditional spinal surgery.